FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Markus Dietlein

Research Profile

Chemicals & Drugs

Disorders

Procedures

Geographic Areas

Germany

Concepts & Ideas

Co-author Network

Publications

TOP 3
Boris Decarolis; Markus Dietlein; Barbara Hero; Frederik Roels; Christina Schneider; Thorsten Simon; Ruth Volland; Frank Berthold; Matthias Schmidt
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Matthias Scheffler; Erich Stoelben; Thomas Zander; Ron Boellaard; Reinhard Büttner; Markus Dietlein; Walburga Engel-Riedel; Lukas Heukamp; Deniz Kahraman; Carsten Kobe; Adriaan A Lammertsma; Bernd Neumaier; Lucia Nogova; Irini Papachristou; Silvia Querings; Jürgen Wolf
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Burkhard Riemann; D Schmidt; Joachim Sciuk; K Uhrhan; Markus Dietlein; R Dorn; T Kodalle; Torsten Kuwert; Otmar Schober
Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Markus Dietlein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Boris Decarolis; Markus Dietlein; Barbara Hero; Frederik Roels; Christina Schneider; Thorsten Simon; Ruth Volland; Frank Berthold; Matthias Schmidt
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(7):944-51.
2013: Matthias Scheffler; Erich Stoelben; Thomas Zander; Ron Boellaard; Reinhard Büttner; Markus Dietlein; Walburga Engel-Riedel; Lukas Heukamp; Deniz Kahraman; Carsten Kobe; Adriaan A Lammertsma; Bernd Neumaier; Lucia Nogova; Irini Papachristou; Silvia Querings; Jürgen Wolf
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
PloS one 2013;8(1):e53081.
2013: Burkhard Riemann; D Schmidt; Joachim Sciuk; K Uhrhan; Markus Dietlein; R Dorn; T Kodalle; Torsten Kuwert; Otmar Schober
Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.
Nuklearmedizin. Nuclear medicine 2013;52(1):1-6.
2012: Thomas Fischer; Jürgen Hescheler; Ralf Kriehuber; Matthias Matzkies; Ekkehard Pomplun; Hans-Dieter Royer; Harald Schicha; Stefan Arnhold; Alexander Dellweg; Markus Dietlein; Ferdinand Sudbrock; Johannes Winkler; Klaus Schomäcker
Cellular response on Auger- and Beta-emitting nuclides: human embryonic stem cells (hESC) vs. keratinocytes.
International journal of radiation biology 2012;88(12):961-71.
2012: Deniz Kahraman; Ronald Boellaard; Markus Dietlein; Arne Holstein; Adriaan A Lammertsma; Bernd Neumaier; Lucia Nogova; Matthias Scheffler; Jürgen Wolf; Thomas Zander; Carsten Kobe
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Clinical nuclear medicine 2012;37(11):1058-64.
2012: Matthias Scheffler; Roman Thomas; Thomas Zander; Markus Dietlein; Deniz Kahraman; Carsten Kobe; Bernd Neumaier; Lucia Nogova; Jürgen Wolf
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
Lung cancer (Amsterdam, Netherlands) 2012;77(3):617-20.
2012: Carsten Kobe; Adriaan A Lammertsma; Bernd Neumaier; Lucia Nogova; Matthias Scheffler; Roland T Ullrich; Jürgen Wolf; Thomas Zander; Ronald Boellaard; Markus Dietlein; Arne Holstein; Deniz Kahraman
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
European journal of nuclear medicine and molecular imaging 2012;39(7):1117-27.
2012: Christina Schneider; Thorsten Simon; Ursula Schulze Uphoff; Hakan Alakus; Frank Berthold; Markus Dietlein; Uta Drebber; Barbara Hero; Elke Holinski-Feder; Matthias C Schmidt
[18F]Fluorodeoxyglucose positron emission tomography/computed tomography-positive gastric adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(14):e140-3.
2012: C Schneider; Matthias Schmidt; Markus Dietlein; Wolfgang Eschner; D Kahraman; Carsten Kobe
Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2012;120(3):160-3.
2012: Matthias C Schmidt; Klara Uhrhan; Richard P Baum; Birgit Cremer; Laura Hasselbring; Sabine Kunze; Birgid Markiefka; Max Schlaak; Markus Dietlein
(68)Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell Carcinoma.
International journal of clinical and experimental medicine 2012;5(4):363-6.
2012: C Schneider; M Faust; D Kahraman; Carsten Kobe; G Malchau; Harald Schicha; Matthias Schmidt; Markus Dietlein
Calcitonin screening in patients with thyroid nodules. Diagnostic value.
Nuklearmedizin. Nuclear medicine 2012;51(6):228-33.
2012: D Kahraman; Carsten Kobe; D J Pedrosa; Markus Dietlein; C Eggers; A Holstein; C Schneider; Lars Timmermann; Matthias Schmidt
123I-FP-CIT SPECT imaging of the dopaminergic state. Visual assessment of dopaminergic degeneration patterns reflects quantitative 2D operator-dependent and 3D operator-independent techniques.
Nuklearmedizin. Nuclear medicine 2012;51(6):244-51.
2012: Guido Michels; Markus Dietlein; Carsten Kobe; Roman Pfister
Mediastinal goiter diagnosed by functional imaging.
The Libyan journal of medicine 2012;7():.
2011: Deniz Kahraman; Ronald Boellaard; Markus Dietlein; Arne Holstein; Adriaan A Lammertsma; Bernd Neumaier; Lucia Nogova; Matthias Scheffler; Roland T Ullrich; Jürgen Wolf; Thomas Zander; Carsten Kobe
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(12):1871-7.
2011: Klaus Schomäcker; Ferdinand Sudbrock; Markus Dietlein; Thomas Fischer; Mark Gaidouk; Carsten Kobe; Harald Schicha
Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.
European journal of nuclear medicine and molecular imaging 2011;38(12):2165-72.
2011: Thomas Zander; Matthias Scheffler; Lucia Nogova; Carsten Kobe; Walburga Engel-Riedel; Martin Hellmich; Irini Papachristou; Karin Toepelt; Andreas Draube; Lukas Heukamp; Reinhard Buettner; Yon D Ko; Roland T Ullrich; Egbert Smit; Ronald Boellaard; Adriaan A Lammertsma; Michael Hallek; Andreas H Jacobs; Andreas Schlesinger; Karin Schulte; Silvia Querings; Erich Stoelben; Bernd Neumaier; Roman K Thomas; Markus Dietlein; Jürgen Wolf
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1701-8.
2011: Markus Dietlein; F A Verburg; Markus Luster; Christoph Reiners; F Pitoia; Harald Schicha
One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer.
European journal of nuclear medicine and molecular imaging 2011;38(5):793-8.
2010: Jan Alexander Krämer; Kurt Werner Schmid; Henning Dralle; Markus Dietlein; Harald Schicha; Hartmut Lerch; Joachim Gerss; Thomas Frankewitsch; Otmar Schober; Burkhard Riemann
Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trial.
European journal of endocrinology / European Federation of Endocrine Societies 2010;163(4):637-44.
2010: Carsten Kobe; Markus Dietlein; Jan Kriz; Christian Furth; Michael Fuchs; Peter Borchmann; Andreas Engert; Hans Theodor Eich
The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
Expert review of anticancer therapy 2010;10(9):1419-28.
2010: Daniel Vallböhmer; Arnulf H Hölscher; Paul M Schneider; Matthias Schmidt; Markus Dietlein; Elfriede Bollschweiler; S Baldus; Hakan Alakus; Jan Brabender; Ralf Metzger; Stefan P Mönig
[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
Journal of surgical oncology 2010;102(2):135-40.
2010: C Dueren; Markus Dietlein; Markus Luster; F Plenzig; R Steinke; J Grimm; P Groth; W Eichhorn; Christoph Reiners
The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2010;118(8):513-9.
2010: Natig Gassanov; Markus Dietlein; Evren Caglayan; Erland Erdmann; Fikret Er
[Amiodarone-induced thyroid gland dysfunctions].
Deutsche medizinische Wochenschrift (1946) 2010;135(16):807-11.
2010: Carsten Kobe; Wolfgang Eschner; Markus Wild; Ilka Rahlff; Ferdinand Sudbrock; Matthias Schmidt; Markus Dietlein; Harald Schicha
Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Nuclear medicine communications 2010;31(3):201-5.
2010: R Lorenz; Markus Dietlein; Christoph Reiners
[Nuclear medical inpatient treatment in Germany - analysis of structured quality reports 2004-2008].
Nuklearmedizin. Nuclear medicine 2010;49(2):49-57.
2010: Markus Dietlein; S M Börner; Thomas Fischer; Hinrich Hansen; Roland Schnell; B Zimmermanns; Samir Tawadros; Andreas Engert; Oliver Staak; Elke Pogge von Strandmann; Carsten Kobe; Harald Schicha; Klaus Schomäcker
Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.
Nuklearmedizin. Nuclear medicine 2010;49(3):97-105.
2010: Wolfgang Eschner; Matthias Schmidt; Markus Dietlein; Harald Schicha
PROLARA: prognosis-based lifetime attributable risk approximation for cancer from diagnostic radiation exposure.
European journal of nuclear medicine and molecular imaging 2010;37(1):131-5.
2009: Daniel Vallböhmer; Arnulf H Hölscher; Markus Dietlein; Elfriede Bollschweiler; Stephan E Baldus; Stefan P Mönig; Ralf Metzger; Harald Schicha; Matthias Schmidt
[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Annals of surgery 2009;250(6):888-94.
2009: Lucia Nogová; Ronald Boellaard; Carsten Kobe; Nikie Hoetjes; Thomas Zander; Stefan Hubert Gross; Sasa Dimitrijevic; Ted Pellas; Wolfgang Eschner; Katja Schmidt; Christopher Bangard; Wendy Hayes; Roman K Thomas; Markus Dietlein; Giuseppe Giaccone; Otto S Hoekstra; Adriaan A Lammertsma; Jürgen Wolf
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(11):1815-9.
2009: Juliane Bachmann; Carsten Kobe; Seher Bor; Ilka Rahlff; Markus Dietlein; Harald Schicha; Matthias Schmidt
Radioiodine therapy for thyroid volume reduction of large goitres.
Nuclear medicine communications 2009;30(6):466-71.
2009: Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha
Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.
European journal of nuclear medicine and molecular imaging 2009;36(5):735-44.
2009: Peter Theissen; Matthias Schmidt; T Ivanova; Markus Dietlein; Harald Schicha
MIBI scintigraphy in hypofunctioning thyroid nodules--can it predict the dignity of the lesion?
Nuklearmedizin. Nuclear medicine 2009;48(4):144-52.
2009: Harald Schicha; M Hellmich; W Lehmacher; Wolfgang Eschner; Matthias Schmidt; Carsten Kobe; Otmar Schober; Markus Dietlein
[Should all patients with thyroid nodules > or = 1 cm undergo fine-needle aspiration biopsy?].
Nuklearmedizin. Nuclear medicine 2009;48(3):79-83.
2008: Christoph Reiners; Markus Dietlein; Markus Luster
Radio-iodine therapy in differentiated thyroid cancer: indications and procedures.
Best practice & research. Clinical endocrinology & metabolism 2008;22(6):989-1007.
2008: Carsten Kobe; Markus Dietlein; Jeremy Franklin; Jana Markova; Andreas Lohri; Holger Amthauer; Susanne Klutmann; WH Knapp; Josee M Zijlstra; Andreas Bockisch; Matthias Weckesser; Reinhard Lorenz; Mathias Schreckenberger; Roland Bares; Hans Theodor Eich; Rolf-Peter Mueller; Michael Fuchs; Peter Borchmann; Harald Schicha; Volker Diehl; Andreas Engert
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Blood 2008;112(10):3989-94.
2008: Christoph Reiners; Markus Dietlein; M Luster
[Malignant goiter--thyroid cancer].
Deutsche medizinische Wochenschrift (1946) 2008;133(43):2215-28; quiz 2229-30.
2008: Markus Luster; S E Clarke; Markus Dietlein; Michael Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Guidelines for radioiodine therapy of differentiated thyroid cancer.
European journal of nuclear medicine and molecular imaging 2008;35(10):1941-59.
2008: Matthias Schmidt; Michael Voell; Ilka Rahlff; Markus Dietlein; Carsten Kobe; Michael Faust; Harald Schicha
Long-term follow-up of antithyroid peroxidase antibodies in patients with chronic autoimmune thyroiditis (Hashimoto's thyroiditis) treated with levothyroxine.
Thyroid : official journal of the American Thyroid Association 2008;18(7):755-60.
2008: Roland Schnell; Markus Dietlein; Klaus Schomäcker; Carsten Kobe; Peter Borchmann; Harald Schicha; Michael Hallek; Andreas Engert
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
Onkologie 2008;31(1-2):49-51.
2008: Carsten Kobe; Markus Dietlein; Christine Mauz-Körholz; Andreas Engert; Peter Borchmann; Osama Sabri; Otmar Schober; Harald Schicha; Regine Kluge
[FDG-PET in Hodgkin lymphoma].
Nuklearmedizin. Nuclear medicine 2008;47(6):235-8; quiz N75-6.
2008: Matthias Schmidt; W Huff; Markus Dietlein; Carsten Kobe; Harald Schicha
[Interactions between brain, psyche and thyroid].
Nuklearmedizin. Nuclear medicine 2008;47(6):225-34.
2008: Markus Dietlein; G Kahaly; Carsten Kobe; Matthias Schmidt; K-M Derwahl; Harald Schicha
[Obesity, energy regulation and thyroid function: is borderline elevated TSH-level the cause or secondary phenomenon of obesity].
Nuklearmedizin. Nuclear medicine 2008;47(5):181-7.
2008: Carsten Kobe; I Weber; Wolfgang Eschner; F Sudbrock; Matthias Schmidt; Markus Dietlein; Harald Schicha
Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?
Nuklearmedizin. Nuclear medicine 2008;47(4):153-6.
2008: Markus Dietlein; Karl Wegscheider; Renate Vaupel; Matthias Schmidt; Harald Schicha
Survey of management of solitary thyroid nodules in Germany.
Nuklearmedizin. Nuclear medicine 2008;47(3):87-96.
2008: Markus Dietlein; H Wieler; Matthias Schmidt; R Schwab; P E Goretzki; Harald Schicha
[Routine measurement of serum calcitonin in patients with nodular thyroid disorders?].
Nuklearmedizin. Nuclear medicine 2008;47(2):65-72.
2008: Carsten Kobe; Wolfgang Eschner; F Sudbrock; I Weber; K Marx; Markus Dietlein; Harald Schicha
Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Nuklearmedizin. Nuclear medicine 2008;47(1):13-7.
2008: Matthias Schmidt; N Thoma; Markus Dietlein; Detlef Moka; Wolfgang Eschner; M Faust; W Schröder; M von Hülst-Schlabrendorff; W Ehses; Harald Schicha
99mTc-MIBI SPECT in primary hyperparathyroidism. Influence of concomitant vitamin D deficiency for visualization of parathyroid adenomas.
Nuklearmedizin. Nuclear medicine 2008;47(1):1-7.
2007: Markus Dietlein; J Dressler; Frank Grünwald; Bernhard Leisner; Ernst Moser; Christoph Reiners; Harald Schicha; Peter Schneider; Otmar Schober
[Guideline for radioiodine therapy for benign thyroid diseases (version 4)].
Nuklearmedizin. Nuclear medicine 2007;46(5):220-3.
2007: Markus Dietlein; J Dressler; Wolfgang Eschner; Frank Grünwald; Michael Lassmann; Bernhard Leisner; Markus Luster; Ernst Moser; Christoph Reiners; Harald Schicha; Otmar Schober
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
Nuklearmedizin. Nuclear medicine 2007;46(5):213-9.
2007: Markus Dietlein; J Dressler; Wolfgang Eschner; Frank Grünwald; Michael Lassmann; Bernhard Leisner; Markus Luster; Christoph Reiners; Harald Schicha; Otmar Schober
[Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)].
Nuklearmedizin. Nuclear medicine 2007;46(5):206-12.
2007: Markus Dietlein; J Dressler; Wolfgang Eschner; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedure guideline for thyroid scintigraphy (version 3)].
Nuklearmedizin. Nuclear medicine 2007;46(5):203-5.
2007: Markus Dietlein; J Dressler; Wolfgang Eschner; Michael Lassmann; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedure guideline for radioiodine test (Version 3)].
Nuklearmedizin. Nuclear medicine 2007;46(5):198-202.
2007: Markus Dietlein; Detlef Moka; U Reinholz; Matthias Schmidt; Klaus Schomäcker; Harald Schicha; U Wellner
Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Nuklearmedizin. Nuclear medicine 2007;46(3):77-84.
2007: Markus Dietlein; Karl Wegscheider; Renate Vaupel; Matthias Schmidt; Harald Schicha
Management of multinodular goiter in Germany (Papillon 2005): do the approaches of thyroid specialists and primary care practitioners differ?
Nuklearmedizin. Nuclear medicine 2007;46(3):65-75.
2006: Matthias Schmidt; Markus Dietlein; Ursula Schröder; Harald Schicha
False-positive uptake of I-131 in a laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid carcinoma.
Clinical nuclear medicine 2006;31(11):716-7.
2006: B Dederichs; Markus Dietlein; B Jenniches-Kloth; Matthias Schmidt; Peter Theissen; Detlef Moka; Harald Schicha
Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2006;114(7):366-70.
2006: Kathrin Marx; Detlef Moka; Klaus Schomäcker; Thomas Fischer; Beate Gabruk-Szostak; Carsten Kobe; Markus Dietlein; Harald Schicha
Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis?
Nuclear medicine communications 2006;27(4):353-8.
2006: Matthias Schmidt; Eva Gorbauch; Markus Dietlein; Michael Faust; Hartmut Stützer; Wolfgang Eschner; Peter Theissen; Harald Schicha
Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.
Thyroid : official journal of the American Thyroid Association 2006;16(3):281-8.
2006: Christina Otto; Markus Jensen; Markus Dietlein; Thomas Fischer; Matthias Schmidt; Samir Tawadros; Sarah Maria Börner; Sebastian Alfred Weber; Rüdiger Spitz; Wilhelm Bloch; Frank Berthold; Harald Schicha; Klaus Schomäcker
Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice.
Nuclear medicine communications 2006;27(2):171-8.
2006: Matthias Schmidt; Thorsten Simon; Barbara Hero; Wolfgang Eschner; Markus Dietlein; F Sudbrock; Rudolf Bongartz; Frank Berthold; Harald Schicha
Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Nuklearmedizin. Nuclear medicine 2006;45(4):145-51; quiz N39-40.
2006: Markus Dietlein; B Dederichs; Carsten Kobe; Peter Theissen; Matthias Schmidt; Harald Schicha
[Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery].
Nuklearmedizin. Nuclear medicine 2006;45(1):21-34; quiz N1-2.
2005: Klaus Schomäcker; Markus Dietlein; Gynter Mödder; Barbara Boddenberg-Pätzold; Beate Zimmermanns; Thomas Fischer; Harald Schicha
Stability of radioactive colloids for radiation synovectomy: influence of X-ray contrast agents, anaesthetics and glucocorticoids in vitro.
Nuclear medicine communications 2005;26(11):1027-35.
2005: Markus Luster; Ralph Felbinger; Markus Dietlein; Christoph Reiners
Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.
Thyroid : official journal of the American Thyroid Association 2005;15(10):1147-55.
2005: Roland Schnell; Markus Dietlein; Jan Oliver Staak; Peter Borchmann; Klaus Schomaecker; Thomas Fischer; Wolfgang Eschner; Hinrich Hansen; Franck Morschhauser; Harald Schicha; Volker Diehl; Andrew Raubitschek; Andreas Engert
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4669-78.
2005: Markus Dietlein; Hendrik Pels; Holger Schulz; Oliver Staak; Peter Borchmann; Klaus Schomäcker; Thomas Fischer; Wolfgang Eschner; Elke Pogge von Strandmann; Harald Schicha; Andreas Engert; Roland Schnell
Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.
European journal of haematology 2005;74(4):348-52.
2005: Markus Dietlein; Harald Schicha
Amiodarone-induced thyrotoxicosis due to destructive thyroiditis: therapeutic recommendations.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2005;113(3):145-51.
2005: Matthias Schmidt; Wolfgang Eschner; Markus Dietlein; Peter Theissen; Harald Schicha
[Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): can they still compete with (18)F-FDG-PET?].
Nuklearmedizin. Nuclear medicine 2005;44(1):37-48; quiz N2-3.
2005: Markus Dietlein; Carsten Kobe; Matthias Schmidt; Harald Schicha
[The incidentaloma of the thyroid. Over- or underuse of diagnostic procedure for an epidemiologic finding?].
Nuklearmedizin. Nuclear medicine 2005;44(5):213-24; quiz N41-2.
2005: Klaus Schomäcker; Markus Dietlein; Roland Schnell; J Pinkert; Wolfgang Eschner; B Zimmermanns; Th Fischer; Andreas Engert; Harald Schicha
[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives].
Nuklearmedizin. Nuclear medicine 2005;44(4):166-77.
2005: Markus Dietlein; Walter A Luyken; Harald Schicha; Antonio Larena-Avellaneda
Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?
Nuclear medicine communications 2005;26(1):3-8.
2004: Markus Dietlein; J Dressler; Frank Grünwald; Bernhard Leisner; Ernst Moser; Christoph Reiners; Harald Schicha; Peter Schneider; Otmar Schober
[Guideline for radioiodine therapy for benign thyroid diseases (version 3)].
Nuklearmedizin. Nuclear medicine 2004;43(6):217-20.
2004: Markus Dietlein; J Dressler; Jamshid Farahati; Frank Grünwald; Bernhard Leisner; Ernst Moser; Christoph Reiners; Harald Schicha; Otmar Schober
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)].
Nuklearmedizin. Nuclear medicine 2004;43(4):115-20.
2004: Markus Dietlein; Otmar Schober; Harald Schicha
[Overtherapy or undertherapy for papillary thyroid microcarcinoma? Therapeutic considerations for radioiodine ablation].
Nuklearmedizin. Nuclear medicine 2004;43(4):107-14.
2004: Matthias Schmidt; M Schmalenbach; Markus Jungehülsing; Peter Theissen; Markus Dietlein; Ursula Schröder; Wolfgang Eschner; Eberhard Stennert; Harald Schicha
18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis.
Nuklearmedizin. Nuclear medicine 2004;43(3):91-101;quiz 102-4.
2003: Markus Dietlein; Detlef Moka; Matthias Schmidt; Peter Theissen; Harald Schicha
[Prevention, screening and therapy of thyroid diseases and their cost-effectiveness].
Nuklearmedizin. Nuclear medicine 2003;42(5):181-9.
2003: Markus Dietlein; W Weber; M Schwaiger; Harald Schicha
[18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer].
Nuklearmedizin. Nuclear medicine 2003;42(4):145-56.
2003: Markus Dietlein; J Dressler; Wolfgang Eschner; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2)].
Nuklearmedizin. Nuclear medicine 2003;42(3):123-5.
2003: Markus Dietlein; J Dressler; Wolfgang Eschner; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedure guideline for thyroid scintigraphy (version 2)].
Nuklearmedizin. Nuclear medicine 2003;42(3):120-2.
2003: Markus Dietlein; J Dressler; Wolfgang Eschner; Michael Lassmann; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedure guideline for radioiodine test (version 2)].
Nuklearmedizin. Nuclear medicine 2003;42(3):116-9.
2003: Markus Dietlein; J Dressler; Frank Grünwald; K Joseph; Bernhard Leisner; Ernst Moser; Christoph Reiners; Johann Rendl; Harald Schicha; Peter Schneider; Otmar Schober
[Guideline for in vivo- and in vitro procedures for thyroid diseases (version 2)].
Nuklearmedizin. Nuclear medicine 2003;42(3):109-15.
2003: Markus Dietlein; Harald Schicha
[Reimbursement of the PET in oncology in Europe: a questionnaire based survey].
Nuklearmedizin. Nuclear medicine 2003;42(3):80-5.
2003: Markus Dietlein; Harald Schicha
[Basedown disease, thyroid gland autonomy, nodular goiter. When is radiotherapy indicated?].
MMW Fortschritte der Medizin 2003;145(17):47-9.
2003: Jan Oliver Staak; Markus Dietlein; Andreas Engert; Martin R Weihrauch; Klaus Schomäcker; Th Fischer; Wolfgang Eschner; Peter Borchmann; Volker Diehl; Harald Schicha; Roland Schnell
[Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects].
Nuklearmedizin. Nuclear medicine 2003;42(1):19-24.
2003: Martin R Weihrauch; Markus Dietlein; Harald Schicha; Volker Diehl; Hans Tesch
Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma.
Leukemia & lymphoma 2003;44(1):15-22.
2002: Matthias Schmidt; Eva Fischer; Markus Dietlein; Olaf Michel; Kerstin Weber; Detlef Moka; Eberhard Stennert; Harald Schicha
Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.
European journal of nuclear medicine and molecular imaging 2002;29(12):1571-80.
2002: Detlef Moka; Markus Dietlein; Harald Schicha
Radioiodine therapy and thyrostatic drugs and iodine.
European journal of nuclear medicine and molecular imaging 2002;29 Suppl 2():S486-91.
2002: Detlef Moka; Markus Dietlein; Klaus Raffelt; Josef Hahn; Harald Schicha
Differentiation between healthy thyroid remnants and tumor tissue after radioiodine therapy in patients with differentiated thyroid carcinoma using in vitro phosphorus-31 magnetic resonance spectroscopy.
The American journal of medicine 2002;112(8):634-41.
2002: Matthias Schmidt; Friedrich Jockenhövel; Peter Theissen; Markus Dietlein; Wilhelm Krone; Harald Schicha
[Assessment of endocrine disorders of the hypothalamic-pituitary axis by nuclear medicine techniques].
Nuklearmedizin. Nuclear medicine 2002;41(2):80-90.
2002: Harald Schicha; Markus Dietlein
[Graves' disease nd toxic nodular goiter--radioiodine therapy].
Nuklearmedizin. Nuclear medicine 2002;41(2):63-70.
2002: Martin R Weihrauch; Daniel Re; S Bischoff; Markus Dietlein; Klemens Scheidhauer; Barbara Krug; F Textoris; Sascha Ansén; Jeremy Franklin; Heribert Bohlen; Jürgen Wolf; Harald Schicha; Volker Diehl; Hans Tesch
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.
Annals of hematology 2002;81(1):20-5.
2001: Martin R Weihrauch; Daniel Re; Klemens Scheidhauer; Sascha Ansén; Markus Dietlein; S Bischoff; Heribert Bohlen; Jürgen Wolf; Harald Schicha; Volker Diehl; Hans Tesch
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Blood 2001;98(10):2930-4.
2001: Michaela Diehl; Jörn H Risse; Katja Brandt-Mainz; Markus Dietlein; K H Bohuslavizki; Peter Matheja; H Lange; Jan Bredow; Carsten Körber; Frank Grünwald
Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.
European journal of nuclear medicine 2001;28(11):1671-6.
2001: Markus Dietlein; Detlef Moka; K Weber; Peter Theissen; Harald Schicha
[Cost-effectiveness of PET in the management algorithms of lung tumors: comparison of health economic data].
Nuklearmedizin. Nuclear medicine 2001;40(4):122-8.
2001: Detlef Moka; Frank M Baer; Peter Theissen; Christian A Schneider; Markus Dietlein; Erland Erdmann; Harald Schicha
Non-Q-wave myocardial infarction: impaired myocardial energy metabolism in regions with reduced 99mTc-MIBI accumulation.
European journal of nuclear medicine 2001;28(5):602-7.
2000: Markus Dietlein; Detlef Moka; Klemens Scheidhauer; Matthias Schmidt; Peter Theissen; Eberhard Voth; Wolfgang Eschner; Harald Schicha
Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic tests.
Nuclear medicine communications 2000;21(11):991-1000.
2000: Markus Dietlein; K Weber; A Gandjour; Detlef Moka; Peter Theissen; Karl Wilhelm Lauterbach; Harald Schicha
Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
European journal of nuclear medicine 2000;27(11):1598-609.
2000: Markus Dietlein; K Weber; A Gandjour; Detlef Moka; Peter Theissen; Karl Wilhelm Lauterbach; Harald Schicha
Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany.
European journal of nuclear medicine 2000;27(10):1441-56.
2000: Barbara Krug; Markus Dietlein; Wolfgang Groth; Hartmut Stützer; T Psaras; Axel Gossmann; Klemens Scheidhauer; Harald Schicha; Klaus Lackner
Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.
Acta radiologica (Stockholm, Sweden : 1987) 2000;41(5):446-52.
2000: Detlef Moka; Eberhard Voth; Markus Dietlein; Antonio Larena-Avellaneda; Harald Schicha
Technetium 99m-MIBI-SPECT: A highly sensitive diagnostic tool for localization of parathyroid adenomas.
Surgery 2000;128(1):29-35.
2000: Detlef Moka; Eberhard Voth; Markus Dietlein; Antonio Larena-Avellaneda; Harald Schicha
Preoperative localization of parathyroid adenomas using 99mTc-MIBI scintigraphy.
The American journal of medicine 2000;108(9):733-6.
2000: Detlef Moka; Wolfgang Eschner; Eberhard Voth; Markus Dietlein; Antonio Larena-Avellaneda; Harald Schicha
Iterative reconstruction: an improvement of technetium-99m MIBI SPET for the detection of parathyroid adenomas?
European journal of nuclear medicine 2000;27(5):485-9.
1999: Frank Grünwald; T Kälicke; U Feine; R Lietzenmayer; Klemens Scheidhauer; Markus Dietlein; Otmar Schober; H Lerch; Katja Brandt-Mainz; W Burchert; G Hiltermann; Uwe Cremerius; Hans-Jürgen Biersack
Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.
European journal of nuclear medicine 1999;26(12):1547-52.
1999: Markus Dietlein; WH Knapp; Karl Wilhelm Lauterbach; Harald Schicha
Economic evaluation studies in nuclear medicine: the need for standardization.
European journal of nuclear medicine 1999;26(6):663-80.
1999: Markus Dietlein; Barbara Krug; Wolfgang Groth; K Smolarz; Klemens Scheidhauer; T Psaras; Hartmut Stützer; Klaus Lackner; Harald Schicha
Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.
Nuclear medicine communications 1999;20(3):255-61.
1999: Markus Dietlein; B Dederichs; A Weigand; Harald Schicha
Radioiodine therapy and thyroid-associated orbitopathy: risk factors and preventive effects of glucocorticoids.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1999;107 Suppl 5():S190-4.
1999: Markus Dietlein; J Dressler; Jamshid Farahati; Bernhard Leisner; Ernst Moser; Christoph Reiners; Harald Schicha; Otmar Schober
[Guidelines for radioiodine therapy (RIT) in differentiated thyroid cancer].
Nuklearmedizin. Nuclear medicine 1999;38(6A):221-2.
1999: Markus Dietlein; J Dressler; K Joseph; Bernhard Leisner; Ernst Moser; Christoph Reiners; Harald Schicha; Peter Schneider; Otmar Schober
[Guidelines for radioiodine therapy (RIT) in benign thyroid diseases].
Nuklearmedizin. Nuclear medicine 1999;38(6A):219-20.
1999: Markus Dietlein; J Dressler; K Joseph; Bernhard Leisner; Ernst Moser; Christoph Reiners; Johann Rendl; Harald Schicha; Otmar Schober
[Guidelines in thyroid diagnosis].
Nuklearmedizin. Nuclear medicine 1999;38(6A):215-8.
1999: Markus Dietlein; J Dressler; Wolfgang Eschner; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedures for iodine-131 whole body scintigraphy in the differential diagnosis of thyroid cancer].
Nuklearmedizin. Nuclear medicine 1999;38(6A):213-4.
1999: Markus Dietlein; J Dressler; Wolfgang Eschner; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedures for the radioiodine test].
Nuklearmedizin. Nuclear medicine 1999;38(6A):211-2.
1999: Markus Dietlein; J Dressler; Wolfgang Eschner; Bernhard Leisner; Christoph Reiners; Harald Schicha
[Procedures for thyroid scintigraphy].
Nuklearmedizin. Nuclear medicine 1999;38(6A):209-10.
1999: Markus Dietlein; Klemens Scheidhauer; Karl Wilhelm Lauterbach; Harald Schicha
[Quality criteria for cost-benefit analysis in oncologic nuclear medicine and state of its realization].
Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 1999;93(1):49-55.
1999: Markus Dietlein; Detlef Moka; B Dederichs; E Hunsche; Karl Wilhelm Lauterbach; Harald Schicha
[Cost-effectiveness analysis: radioiodine or antithyroid medication in primary treatment of immune hyperthyroidism].
Nuklearmedizin. Nuclear medicine 1999;38(1):7-14.
1998: Markus Dietlein; Karl Wilhelm Lauterbach; Harald Schicha
Treatment of toxic nodular goitres: Comparative costing of radioiodine therapy and surgery.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1998;106 Suppl 4():S66-70.
1998: Markus Dietlein; CJ Troche; Detlef Moka; V Bausch; Karl Wilhelm Lauterbach; Harald Schicha
[Consequences of new patient discharge guidelines on the cost structure of radioiodine therapy].
Nuklearmedizin. Nuclear medicine 1998;37(1):33-40.
1998: Markus Dietlein; Klemens Scheidhauer; Eberhard Voth; Peter Theissen; Harald Schicha
Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Nuklearmedizin. Nuclear medicine 1998;37(1):12-7.
1997: Markus Dietlein; Klemens Scheidhauer; Eberhard Voth; Peter Theissen; Harald Schicha
Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.
European journal of nuclear medicine 1997;24(11):1342-8.
1997: Markus Dietlein; L Geckle; T Overbeck; Detlef Moka; V Bausch; CJ Troche; Karl Wilhelm Lauterbach; Harald Schicha
[Cost minimization analysis for the definitive therapy of hyperthyroidism: comparison of goiter resection with radioiodine therapy].
Nuklearmedizin. Nuclear medicine 1997;36(5):150-6.
1997: H Schicha; Markus Dietlein
[Radioiodine therapy in differentiated thyroid gland carcinoma].
Zentralblatt für Chirurgie 1997;122(4):266-73.
1993: Barbara Krug; Roman Fischbach; S Herrmann; Markus Dietlein; T Küpper; W Dölken; U Harnischmacher
[X-ray studies of the peripheral joints: a comparison of digital luminescence radiography (DLR) and film-screen systems].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1993;158(2):133-40.
1992: W Féaux de Lacroix; Markus Dietlein; J Schmidt; Hartmut Stützer
Histological investigation for comparison of cartilaginous tumors of unknown biological course with unequivocal chondrosarcomas.
Zentralblatt für Pathologie 1992;138(5):339-43.
1992: Markus Dietlein; R Schröder; BRIGITTE WIDEMANN; Gabriele Benz-Bohm
Dysplastic gangliocytoma of cerebellum in a newborn. Diagnosis by ultrasonography and MRI.
Pediatric radiology 1992;22(2):131-3.
1992: Markus Dietlein; Gabriele Benz-Bohm; BRIGITTE WIDEMANN
The fibrous metaphyseal defect in early stage. Differential diagnosis to metaphysitis.
Pediatric radiology 1992;22(6):461-2.
1991: E Dietlein; Markus Dietlein; W Theelen; W Möckel
[Haemophilus aphrophilus--a rare endocarditis pathogen].
Medizinische Klinik (Munich, Germany : 1983) 1991;86(7):380-1.
1990: Markus Dietlein; R Lorenz; J Schmidt
[Juxta-articular osteoid osteoma--Image morphology and diagnosis].
Aktuelle Traumatologie 1990;20(6):288-91.
1990: R Lorenz; G P Krestin; Markus Dietlein
[Indications and applicability of sonography or endosonography in cases of diseases of the bladder and prostate].
Röntgen-Blätter; Zeitschrift für Röntgen-Technik und medizinisch-wissenschaftliche Photographie 1990;43(10):430-4.
1990: Markus Dietlein; F E Zanella; W Féaux de Lacroix
[A unicameral aneurysmal bone cyst of the cervical spine. The differential diagnosis of a lateral cervical cyst].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1990;152(6):732-3.
1990: Markus Dietlein; R Lorenz
[Fibrous metaphyseal defect--a stage- and age-dependent differential diagnosis].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1990;152(6):682-6.
1990: Barbara Krug; W Steinbrich; Markus Dietlein; R Lorenz; A Altenburg; T Küpper
[Abdominal x-ray diagnosis using digital luminescent radiography--a comparison with conventional film-screen systems].
Röntgen-Blätter; Zeitschrift für Röntgen-Technik und medizinisch-wissenschaftliche Photographie 1990;43(5):181-7.
1990: Markus Dietlein; W Féaux de Lacroix; K F Neufang; W Steinbrich; J Schmidt
[Assessment of the grading of cartilaginous tumors of the long tubular bones from the radiologic and pathologic viewpoint].
Röntgen-Blätter; Zeitschrift für Röntgen-Technik und medizinisch-wissenschaftliche Photographie 1990;43(5):174-80.
1990: Markus Dietlein; W Féaux de Lacroix
[Parosteal osteosarcoma: an unusual location in the tarsus].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1990;152(2):238-40.
1990: Barbara Krug; W Steinbrich; R Lorenz; S Glathe; Markus Dietlein; J Schirrmeister
[Colonic contrast enema in digital luminescent radiography (DLR) and conventional x-ray technic].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1990;152(2):131-6.
1990: Markus Dietlein
[Osteolysis as a leading symptom of primary hyperparathyroidism].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1990;152(1):111-2.
1990: A Hoffmann; Richard Brunner; A Barth; Markus Dietlein; J Gluch; C Hendricks; H M Steffen
[Early diagnostic criteria of ankylosing spondylitis in patients with acute anterior uveitis].
Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 1990;87(6):560-1.
1989: Markus Dietlein; R Lorenz
[Diagnosis of intramural hematoma of the colon].
Röntgen-Blätter; Zeitschrift für Röntgen-Technik und medizinisch-wissenschaftliche Photographie 1989;42(3):108-13.